[20]
Peyressatre, M.; Prével, C.; Pellerano, M.; Morris, M.C. Targeting cyclin-dependent kinases in human cancers: From small molecules to peptide inhibitors. 2015, 7, 179-237.
[22]
Cyclin-Dependent Kinase (CDK) inhibitors. In: Methods and Protocols;; Orzáez, M; Sancho, Medina; Pérez-Payá, E, Eds.; Humana Press, Springer: New York, 2016.
[25]
Johnson, J.; Thijssen, B.; McDermott, U.; Garnett, M.; Wessels, L.F.A.; Bernards, R. Targeting the RB-E2F pathway in breast cancer. Oncogene, 2016, 35, 4829-4835.
[32]
Asghar, U.; Witkiewicz, A.K.; Turner, N.C.; Knudsen, E.S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov., 2015, 14, 130-146.
[51]
Wood, A.C.; Krytska, K.; Ryles, H.; Sano, R.; Li, N.; King, F.; Smith, T.; Tuntland, T.; Kim, S.; Caponigro, G.; He, Y.Q.; Jennifer, H.; Mosse, Y. Combination CDK4/6 and ALK inhibition demonstrates on-target synergy against neuroblastoma. In: AACR Annual Meeting;; American Association for Cancer Research: San Diego, CA, 2014; 74, .
[52]
Sosman, J.A.; Kittaneh, M.; Lolkema, M.P.J.K.; Postow, M.A.; Schwartz, G.; Franklin, C.; Matano, A.; Bhansali, S.; Parasuraman, S.; Kim, K. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS -mutant melanoma: Early encouraging clinical activity. In: American Society of Clinical Oncology (ASCO) Annual Meeting I; , 2014; 32, pp. 9009-9009.
[75]
Li, X.; Sun, P.; Lan, J.; Peng, J.; Chen, Y.; Wang, B.; Dong, Q. Pyridino[2,3-d]pyrimidin-7(8H)-one derivatives as CDK4 and/or CDK6 inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. W.O. Patent 2014183520A1, November 20, 2014.
[78]
Wan, H.; Xu, Z.; Shi, C.; Li, C.; Xu, Z.; Xia, G. Preparation of fused heterocyclic compounds for treatment of cyclin-dependent kinase related diseases C.N. Patent 105481858A, April 11, 2016.
[80]
Besong, G.; Brain, C.; Brooks, C.; Congreve, M.; Dagostin, C.; He, G. Preparation of pyrrolopyrimidine compounds as CDK inhibitors. W.O Patent 2010020675A1, February 25, 2010.
[81]
Liu, B.; Zhang, Y.; Nie, L.; Bai, S.; Guan, M.; Li, X. 6-[2- (Pyridinyl-2-Ylamino)pyrimidin-4-yl]imidazole compounds as CDK inhibitors and their preparation. W.O. Patent 2016015605A1, February 4, 2016.
[82]
Wang, S.; Chen, K.; Liu, X.; Hu, Y.; Liu, B.; Peng, Y.; Et, A. Preparation of substituted pyrrolopyrimidine derivative as CDK inhibitor. W.O. Patent 2017162215A1, September 28, 2017.
[84]
O’Leary, B.; Finn, R.S.; Turner, N.C. Treating cancer with selective CDK4/6 inhibitors. Nat. Rev. Clin. Oncol., 2016, 13, 416-430.
